For licensed healthcare professionals. The protocol figures below are drawn from published labeling and peer-reviewed literature for educational reference. They are not a prescription, not a recommendation, and not a substitute for the dispensing pharmacy's labeling or your own clinical judgment.

Metabolic

AOD-9604

aka GH fragment 176-191

Not WADA-listed

C-terminal fragment of human GH studied for lipolysis without affecting glucose or IGF-1. Did not meet endpoints in obesity trials.

At a glance

Common vial size: 5 mg
Reference dose: 300 mcg
Frequency: Daily

Reference titration protocol

300 mcg daily.

Reference titration ladder for AOD-9604
Step	Dose	Duration	Administrations / week
1	300 mcg	4 weeks	7×

Reconstitution example

A 5 mg vial reconstituted with 2 mL of bacteriostatic water yields 2.5 mg/mL. Confirm the diluent and volume against the labeling that ships with the vial.

Open this configuration in the calculator

Available formulations

Presentations carried across the VitaRelay pharmacy network, including 503A compounded, 503B outsourcing facility, and research & development sourcing. Pricing and state-level availability are shown to verified accounts only.

12 mg · Injectable503A
12 mg/5ml · Injectable503A
300 mcg · Troche503A
6 mg · Injectable503A
6 mg/5ml · Injectable503A
Lyophilized PowderRUO

References

Heffernan et al., J Endocrinol 2001

Often used with

Compounds commonly discussed alongside AOD-9604 in published protocols and prescriber requests. Listed for reference only — not a clinical recommendation, and not a suggestion to co-administer.

Pricing and ordering are for verified accounts

VitaRelay serves licensed practices, prescribers, and pharmacies. Catalog pricing, availability by state, and ordering are available after your account is verified.

Also in Metabolic

5-Amino-1MQ

Small-molecule NNMT inhibitor under study for adipose-tissue methyl donor preservation, fat loss, and sarcopenia. Oral capsule.

Adipotide

Pro-apoptotic targeted peptide that disrupts adipose vasculature. Preclinical only; nephrotoxicity observed at high doses.

AICAR

AMPK activator studied for exercise mimetic and metabolic effects. WADA-prohibited as a metabolic modulator.

MOTS-c

Mitochondrial-derived peptide implicated in metabolic homeostasis and insulin sensitivity. Preclinical/early human research only.

Tesofensine

Triple monoamine reuptake inhibitor in Phase III for obesity (TIPO-4). Oral, once daily.

Educational information for licensed healthcare professionals

The material on this page is general educational information intended for licensed healthcare professionals and their clinical staff. It is not medical advice, is not a substitute for professional judgment, and does not establish a provider-patient relationship. Nothing here should be read as a recommendation for, or endorsement of, any specific therapy, product, or course of treatment. Compounded preparations must be handled in accordance with applicable federal and state law, the dispensing pharmacy's labeling, and your own institutional policies. All clinical decisions — including product selection, preparation, dosing, and administration — remain the sole responsibility of the treating licensed practitioner.

VitaRelay is a technology and logistics network. We are not a pharmacy, prescriber, or distributor. See our Terms of Service and service availability for details.